These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33544829)

  • 1. N-glycan-mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP.
    Ercig B; Graça NAG; Kangro K; Arfman T; Wichapong K; Hrdinová J; Kaijen P; van Alphen FPJ; van den Biggelaar M; Vanhoorelbeke K; Veyradier A; Coppo P; Reutelingsperger C; Nicolaes GAF; Männik A; Voorberg J
    Blood; 2021 May; 137(19):2694-2698. PubMed ID: 33544829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF.
    Pos W; Crawley JT; Fijnheer R; Voorberg J; Lane DA; Luken BM
    Blood; 2010 Feb; 115(8):1640-9. PubMed ID: 20032502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura.
    Graça NAG; Ercig B; Carolina Velásquez Pereira L; Kangro K; Kaijen P; Nicolaes GAF; Veyradier A; Coppo P; Vanhoorelbeke K; Männik A; Voorberg J
    Haematologica; 2020 Nov; 105(11):2619-2630. PubMed ID: 33131251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
    Roose E; Vidarsson G; Kangro K; Verhagen OJHM; Mancini I; Desender L; Pareyn I; Vandeputte N; Vandenbulcke A; Vendramin C; Schelpe AS; Voorberg J; Azerad MA; Gilardin L; Scully M; Dierickx D; Deckmyn H; De Meyer SF; Peyvandi F; Vanhoorelbeke K
    Thromb Haemost; 2018 Oct; 118(10):1729-1742. PubMed ID: 30235483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura.
    Velásquez Pereira LC; Roose E; Graça NAG; Sinkovits G; Kangro K; Joly BS; Tellier E; Kaplanski G; Falter T; Von Auer C; Rossmann H; Feys HB; Reti M; Prohászka Z; Lämmle B; Voorberg J; Coppo P; Veyradier A; De Meyer SF; Männik A; Vanhoorelbeke K
    J Thromb Haemost; 2021 Feb; 19(2):478-488. PubMed ID: 33171004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.
    Tersteeg C; Verhenne S; Roose E; Schelpe AS; Deckmyn H; De Meyer SF; Vanhoorelbeke K
    Expert Rev Hematol; 2016; 9(2):209-21. PubMed ID: 26581428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.
    Schelpe AS; Roose E; Joly BS; Pareyn I; Mancini I; Biganzoli M; Deckmyn H; Voorberg J; Fijnheer R; Peyvandi F; De Meyer SF; Coppo P; Veyradier A; Vanhoorelbeke K
    Haematologica; 2019 Jun; 104(6):1268-1276. PubMed ID: 30523052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
    Thomas MR; de Groot R; Scully MA; Crawley JT
    EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.
    Halkidis K; Zheng XL
    J Thromb Haemost; 2022 Oct; 20(10):2197-2203. PubMed ID: 35842925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro.
    Ostertag EM; Kacir S; Thiboutot M; Gulendran G; Zheng XL; Cines DB; Siegel DL
    Transfusion; 2016 Jul; 56(7):1763-74. PubMed ID: 27040144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura.
    Luken BM; Kaijen PH; Turenhout EA; Kremer Hovinga JA; van Mourik JA; Fijnheer R; Voorberg J
    J Thromb Haemost; 2006 Nov; 4(11):2355-64. PubMed ID: 16898953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura.
    Luken BM; Turenhout EA; Hulstein JJ; Van Mourik JA; Fijnheer R; Voorberg J
    Thromb Haemost; 2005 Feb; 93(2):267-74. PubMed ID: 15711742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
    Yamaguchi Y; Moriki T; Igari A; Nakagawa T; Wada H; Matsumoto M; Fujimura Y; Murata M
    Thromb Res; 2011 Aug; 128(2):169-73. PubMed ID: 21496883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
    Jian C; Xiao J; Gong L; Skipwith CG; Jin SY; Kwaan HC; Zheng XL
    Blood; 2012 Apr; 119(16):3836-43. PubMed ID: 22289888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADAMTS13 and von Willebrand factor interactions.
    Zander CB; Cao W; Zheng XL
    Curr Opin Hematol; 2015 Sep; 22(5):452-9. PubMed ID: 26186678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome.
    Casina VC; Hu W; Mao JH; Lu RN; Hanby HA; Pickens B; Kan ZY; Lim WK; Mayne L; Ostertag EM; Kacir S; Siegel DL; Englander SW; Zheng XL
    Proc Natl Acad Sci U S A; 2015 Aug; 112(31):9620-5. PubMed ID: 26203127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired TTP: ADAMTS13 meets the immune system.
    Verbij FC; Fijnheer R; Voorberg J; Sorvillo N
    Blood Rev; 2014 Nov; 28(6):227-34. PubMed ID: 25213289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique case of autoantibody mediated inactivation of ADAMTS13 in an Indian TTP patient.
    Bhakuni T; Singhal R; Annarapu GK; Sharma A; Mahapatra M; Saxena R; Guchhait P
    Blood Cells Mol Dis; 2019 Jul; 77():29-33. PubMed ID: 30953939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura].
    Matsumoto M
    Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(2):95-103. PubMed ID: 23629429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overlapping ADAMTS13 peptide binding profiles of DRB1∗08:03 and DRB1∗11:01 suggest a common etiology of immune-mediated thrombotic thrombocytopenic purpura.
    Sakai K; Miyadera H; Kubo M; Nakajima F; Matsumoto M
    J Thromb Haemost; 2023 Mar; 21(3):616-628. PubMed ID: 36696200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.